Navigating clinical research challenges in spondyloarthritis: Insights from the French Spondyloarthritis Taskforce (FAST)

Preconception, pregnancy and postpartum periods in spondyloarthritis: Unmet needs and challenges from a patients and rheumatologists surveys

The changing face of axial spondyloarthritis over the last 25 years

Concordance and agreement between different activity scores in polymyalgia rheumatica

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study

Unmet needs in axial spondyloarthritis. Proceedings of the French spondyloarthritis taskforce workshop

Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia rheumatica

Repurposing the Fibrosis-4 Score in Rheumatoid Arthritis: Data from the ESPOIR Cohort

Type 1 interferons: A target for immune-mediated inflammatory diseases (IMIDs)

Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases

COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection

How to optimize recruitment strategies of patients with rheumatic and musculoskeletal diseases for online surveys: experience from an international study

Current Pharmacological Therapies for the Management of Spondyloarthritis: Special Considerations in Older Patients

Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome

Different anti-SARS-CoV-2 vaccine response under B- and T-cell targeted therapies versus anti-cytokine therapies in patients with inflammatory arthritides

The history of lupus throughout the ages

Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries

Responding to and Driving Change in Rheumatology: Report from the 12th International Immunology Summit 2021

Psoriatic arthritis with hyperuricemia: more peripheral, destructive, and challenging to treat

Excess of Post-Acute Sequelae of COVID-19 After the First Wave of the Pandemic

Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren's disease

Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis

Alteration of innate lymphoid cell homeostasis mainly concerns salivary glands in primary Sjögren's syndrome

Non-primary Sjogren's Syndrome: Secondary or associated?

Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by Wang et al

Identification of new candidate drugs for primary Sjögren's syndrome using a drug repurposing transcriptomic approach

Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by de Wolff et al

Variability of Primary Sjögren's Syndrome Is Driven by Interferon-α and Interferon-α Blood Levels Are Associated With the Class II HLA-DQ Locus

Polymyalgia rheumatica associated with primary Sjögren's syndrome: A French multicentric retrospective study

Inclusion body myositis and Sjögren's syndrome: the association works both ways

Comment on: Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESS: Reply

Subset of DN Memory B Cells Expressing Low Levels of Inhibitory Receptor BTLA Is Enriched in SLE Patients

Prevalence and characteristics of, and knowledge related to, photosensitivity in patients with lupus erythematosus: the international PHOTOLUP study

New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review

New and future therapies: Changes in the therapeutic armamentarium for SLE

IL-17 inhibitors in axial spondyloarthritis. An overview

Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2-5 and MAXIMISE studies

New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL study

Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica

Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial

Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial

Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study

Advancing medical training with augmented reality and haptic feedback simulator: outcomes of a randomized controlled trial on lumbar puncture

Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study

Safety and efficacy of colchicine in crystal-induced arthritis flare in 54 patients with severe chronic kidney disease

The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: A systematic review of clinical trials

The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials

The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: A systematic review of clinical trials

The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials

Use of corticosteroid therapy in persistent synovitis following septic arthritis in adults: Report of 12 cases

Is there still a place for methotrexate in severe psoriatic arthritis?

Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)

When generative artificial intelligence answers to Google Trends about spondyloarthritis: what does a French expert panel think about it?